Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Meta Expands AI Training With Employee Activity Tracking Tools 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
NEWARK, Calif., March 30, 2017 -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies for specialty and orphan diseases with high unmet medical need, today announced that management will provide a corporate overview at the H.C. Wainwright & Co. 1st Annual NASH Investor Conference, being held April 3, 2017 at the St. Regis Hotel in New York City, and the BioCentury Future Leaders in the Biotech Industry Conference, being held April 7 at the Millennium Broadway Hotel & Conference Center in New York City.
| 1st Annual NASH Investor Conference | |
| Date: | Monday, April 3 |
| Time: | 11:40am Eastern Time |
| Location: | St. Regis Hotel, New York City |
| Webcast: | http://ir.cymabay.com/events |
| BioCentury Future Leaders in the Biotech Industry Conference | |
| Date: | Friday, April 7 |
| Time: | 1:30pm Eastern Time |
| Location: | Millennium Broadway Hotel & Conference Center, New York City, NY |
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Seladelpar is a potent, selective, orally active PPARδ agonist. A Phase 2 study of seladelpar in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has completed Phase 2 studies for seladelpar in subjects with primary biliary cholangitis and homozygous familial hypercholesterolemia, establishing proof-of-concept in both indications. Arhalofenate, CymaBay’s other product candidate, is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in subjects with gout. Arhalofenate has been found to reduce painful flares in joints while at the same time lowering serum uric acid by promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. Arhalofenate has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc. CymaBay retains full development and commercialization rights for arhalofenate outside the U.S.
For additional information about CymaBay visit www.cymabay.com.
Contact: Sujal Shah CymaBay Therapeutics, Inc. (510) 293-8800 [email protected] Hans Vitzthum LifeSci Advisors, LLC 212-915-2568 [email protected]
